Biocracked
←

#arterial stiffness

1 article
A bright, minimalist editorial still life on a pale warm-white stone surface, shot from a slightly elevated three-quarter angle in soft natural window light. At center, a small amber glass supplement bottle with a matte cream label, unbranded, sits beside a few loose white capsules. A pair of weathered hands in a light oatmeal linen sleeve, belonging to an older adult, rests gently near the bottle, with a ceramic mug of tea just out of focus. To the right, a clean glass vial and a delicate glass beaker filled with clear liquid catch the light, hinting at laboratory research without any futuristic touch. A small paper notebook with a handwritten simple line graph rising in a gentle curve lies open nearby, along with a sharpened pencil. Scattered at the edges are soft sprigs of dried eucalyptus and a few pale sage-green leaves, adding an organic note. A faint, abstract molecular diagram printed in muted teal ink on a card leans against the bottle, subtle and graphic. The palette is calm and modern: warm ivory, sage green, soft teal, muted amber, and touches of dusty peach. Long, gentle shadows fall across the surface, and the shallow depth of field blurs the background into creamy neutral tones. The composition leaves generous negative space on the left third for headline text. The overall feel is a trendy health and science journal: clean, airy, trustworthy, and quietly sophisticated, with fine film-like grain and true-to-life color. Ultra-detailed, 16:9 landscape.
supplements

1 000 mg de nicotinamida ribósido al día aumentaron el NAD⁺ de las células sanguíneas en aproximadamente un 60 % en adultos mayores, según un ensayo aleatorizado

BY DR. SYNAPSE ·

Un ensayo cruzado publicado en 2018 en *Nature Communications* evaluó nicotinamida ribósido a 500 mg dos veces al día (1 000 mg/día) durante seis semanas en adultos sanos de mediana edad y mayores. El suplemento se toleró bien y elevó el NAD⁺ en las células sanguíneas del sistema inmunitario en torno al 60 % frente al placebo. Los investigadores también observaron indicios preliminares de disminución de la presión arterial y de la rigidez arterial, pero los describen como hipótesis para futuros estudios, no como beneficios demostrados. Este artículo explica por qué se piensa que el NAD⁺ disminuye con la edad, qué hizo el estudio y qué no puede decirnos sobre resultados de enfermedad o longevidad.

This page is available in